Journal List > Korean J Hematol > v.40(4) > 1032635

Chun, Park, Park, Yun, Yang, Park, Yun, Jo, Kwon, and Kim: Pernicious Anemia: A Retrospective Analysis of 22 Cases

Abstract

Background

Pernicious anemia is the most common cause of vitamin B12 deficiency in western populations, but to date, only case reports or small series dealing with this malady have been reported in Korea. This study describes the clinical characteristics of pernicious anemia in Koreans.

Methods

We retrospectively analyzed the clinical data for twenty-two Korean patients with pernicious anemia who were diagnosed during the period from 1995 to 2004 at Chungnam National University Hospital.

Results

Only two patients were diagnosed before 2000. The median age of the patients was 66 years and the male/female ratio was 1.8. Anemia-associated discomfort was the most common symptom (95.5%); this was followed by gastrointestinal and neurological symptoms (77.2% and 50.0%, respectively). Autoimmune disorders were found in five patients (22.7%). The median hemoglobin level was 7.0g/dL (range: 3.1~11.8g/dL) and pancytopenia was found in 12 patients (54.5%). The median serum vitamin B12 Level was 26pg/mL (range: 12~189pg/mL). Fifteen (78.9%) and eight (42.1%) of the 19 patients who underwent tests for antibodies were positive for anti-intrinsic factor and anti-parietal cell antibody, respectively. Nineteen of 21 patients who were treated with intramuscular cobalamin recovered from their cytopenia within 3 months. The gastrointestinal symptoms resolved completely for all the patients, while neurological symptoms remained for some of the patients.

Conclusion

This study shows that the clinical features of pernicious anemia in Koreans are not different from those of the western cases. In addition, pernicious anemia is not a rare finding in Korea.

REFERENCES

1). Babior BM, Bunn HF. Megaloblastic anemia. Kasper DL, Braunwald E, Fauci AS, editors. Harrison's principles of internal medicine. 16th ed.New York: McGrqw Hill Co;2006. p. 601–7.
2). Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997; 337:1441–8.
crossref
3). Borch K, Liedberg G. Prevalence and incidence of pernicious anemia. An evaluation for gastric screening. Scand J Gastroenterol. 1984; 19:154–60.
4). Park AJ, Kim HT, Kim SS, Kim SG, Son YA. Clinical and laboratory diagnosis of pernicious anemia (one case report). Korean J Hematol. 1983; 18:217–23.
5). Lee DG, Do IH, Kim DW, Park JI, Chung SY, Moon SK. A case of pernicious anemia associated with chronic atropic gastritis. Korean J Hematol. 1987; 22:115–20.
6). Hahn JS, Park JO, Lee S, et al. A case of pernicious anemia with autoimmune hemolytic anemia. Korean J Hematol. 1995; 30:315–20.
7). Lee JS, Jeon JJ, Suh JI, et al. Clinical consideration of vitamin B12 deficiency megaloblastic anemia. Korean J Hematol. 1994; 29:259–67.
8). Song HH, Kwon JH, Kim JH, et al. Causes and clinical features of vitamin B12 deficiency megaloblastic anemia. Korean J Hematol. 2004; 39:243–8.
9). Castle WB. Current concept of pernicious anemia. Am J Med. 1970; 48:541–8.
10). Carmel R, Green R, Rosenblatt DS, Watkins D. Update on cobalamin, folate, and homocysteine. Hematology. 2003. 62–81.
crossref
11). Carmel R. Pepsinogens and other serum markers in pernicious anemia. Am J Clin Pathol. 1988; 90:442–5.
crossref
12). Andres E, Loukili NH, Noel E, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ. 2004; 171:251–9.
crossref
13). Chanarin I. Historical review: a history of pernicious anaemia. Br J Haematol. 2000; 111:407–15.
14). Toh BH, Alderuccio F. Pernicious anemia. Autoimmunity. 2004; 37:357–61.
15). Andres E, Perrin AE, Demangeat C, et al. The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine. A monocentric cohort study of 80 patients. Eur J Intern Med. 2003; 14:221–6.
16). Rice L. Food-cobalamin malabsorption: a usual cause of vitamin B12 deficiency. Arch Intern Med. 2000; 160:2061–2.
17). Carmel R. Reassessment of the relative prevalence of antibodies to gastric parietal cell and to intrinsic factor in patients with pernicious anaemia: influence of patients age and race. Clin Exp Immunol. 1992; 89:74–7.
18). Carmel R. Malabsorption of food cobalamin. Bail-lieres Clin Haematol. 1995; 8:639–55.
19). Antony AC. Megaloblastic anemias. Hoffman R, Benz EJ, Shattil SJ, editors. Hematology: basic principles and practice. 4th ed.New York: Churchill Livingstone;2006. p. 533–4.
crossref
20). Perez-Perez GI. Role of Helicobacter pylori infection in the development of pernicious anemia. Clin Infect Dis. 1997; 25:1020–2.
21). Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer. 1993; 71:745–50.
crossref
22). SjobLom SM, Sipponen P, Jarvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993; 34:28–32.
crossref

Fig. 1.
Annual distribution of the numbers of newly diagnosed patients with megaloblastic anemia associated with cobalamin deficiency.
kjh-40-219f1.tif
Table 1.
Causes of vitamin B12 deficiency in megaloblastic anemia (n=58)
Causes No. of patients (%)
Pernicious anemia 22 (37.9)
Gastrectomy 27 (46.6)
Others 9 (15.5)
Table 2.
Patient characteristics (n=22)
Age (yrs, median (range)) 66 (34~79)
Sex (male: female) 14: 8
Duration of symptoms (mos, median (range)) 3 (1~24)
Associated diseases (n (%))  
Hashimoto's thyroiditis 2 (9.1%)
Vitiligo 3 (13.6%)
Graves' disease 2 (9.1%)
Aplastic anemia 2 (9.1%)
Table 3.
Symptoms and signs (n=22)
Manifestations No. of patients (%)
Weakness 20 (90.9)
Headache 10 (45.5)
Exertional dyspnea 10 (45.5)
Sore tongue 16 (72.7)
Anorexia 10 (45.5)
Vertigo 3 (13.6)
Jaundice 2 (9.1)
Numbness 10 (45.5)
Amnesia (forgetfulness) 4 (18.2)
Psychosis 1 (4.5)
Table 4.
Laboratory findings at the time of diagnosis
Findings No. of patients (%)
Leukopenia (<4,000/mL) 13/22 (59.1)
Hemoglobin (g/dL)
 <7 10/22 (45.5)
 7~10 10/22 (45.5)
 >10 2/22 (9.1)
MCV (fL)
 <100 3/22 (13.6)
 100~120 10/22 (45.5)
 >120 9/22 (40.9)
Platelet (×103/μL)
 <50 5/22 (22.7)
 50~130 10/22 (45.5)
 >130 7/22 (31.8)
LDH >450IU/L 17/22 (77.2)
Total bilirubin >1.5mg/dL 10/22 (45.5)
Vitamin B12 (pg/mL)
 <50 14/22 (63.6)
 50~100 3/22 (13.6)
 100~200 5/22 (22.7)
Antibodies
 Anti-intrinsic factor antibody (+) 15/19 (78.9)
 Anti-parietal cell antibody (+) 8/19 (42.1)
 Both antibodies (+) 4/19 (21.1)
 Any antibody (+) 19/19 (100)
PB morphology  
 Hypersegmented neutrophils 20/22 (90.9)
BM study
 Erythroid hyperplasia 19/21 (90.4)
 Hypercellularity 12/21 (57.1)

Abbreviations: MCV, mean corpuscular volume; LDH, lactate dehydrogenase; PB, peripheral blood; BM, bone marrow

Table 5.
Gastroscopic and histologic findings
Findings No. of patients (%)
Gastroscopy (n=21)
 Chronic atropic gastritis 21/21 (100)
  Moderate 10/21 (47.6)
  Severe 11/21 (52.4)
 Others 2/21 (9.5)
  Stomach cancer 1/21 (4.8)
  Hyperplastic polyp 1/21 (4.8)
Histology of body (n=10)
 Atropic gastritis 10/10 (100)
 Intestinal metaplasia 5/10 (50)
 Advanced stomach cancer 1/10 (10)
Test for H. pylori (n=5)
 Positive 0/5 (0)
 Negative 5/5 (100)
Table 6.
Responses to cobalamin therapy (n=21)
Parameters No. of patients (%)
Correction of anemia 19/21 (90.5)
Correction of leucopenia 11/13 (84.6)
Correction of thrombocytopenia 9/11 (81.8)
Resolution of symptoms
 Weakness 20/20 (100)
 Exertional dyspnea 10/10 (100)
 Vertigo 3/3 (100)
 Sore tongue 16/16 (100)
 Anorexia 10/10 (100)
 Headache 10/10 (100)
 Numbness 6/10 (60)
 Amnesia (forgetfulness) 0/4 (0)
TOOLS
Similar articles